✓ Balanced Reporting [9/10]: The headline clearly states the key development — the White House preparing to replace FDA Commissioner Marty Makary — without exaggeration or editorializing, and is substantiated by the article’s content.

"White House prepares to replace FDA leader Marty Makary amid agency turmoil"

✕ Framing by Emphasis [5/10]: The headline emphasizes 'turmoil' which sets a tone of instability, potentially framing Makary negatively, though the article does provide evidence of internal conflict and departures.

"White House prepares to replace FDA leader Marty Makary amid agency turmoil"

✕ Loaded Language [6/10]: The term 'turmoil' in the headline and repeated use of 'criticism,' 'ire,' and 'sidelined' carry negative connotations that subtly frame Makary’s tenure as disruptive or controversial.

"amid agency turmoil"

✕ Editorializing [5/10]: Describing Makary as someone who 'rose to further prominence by criticizing the medical establishment' introduces a subjective interpretation of his public role.

"He rose to further prominence by criticizing the medical establishment amid the coronavirus pandemic."

✓ Proper Attribution [9/10]: The article consistently attributes claims to sources, especially anonymous ones, and avoids presenting speculation as fact, supporting objectivity.

"according to two individuals who spoke on the condition of anonymity to describe internal operations."

✕ Vague Attribution [7/10]: Multiple key claims are attributed to 'two individuals' or 'people' without identifying their roles or positions, weakening the ability to assess source credibility.

"according to two individuals who spoke on the condition of anonymity to describe internal operations."

✓ Comprehensive Sourcing [8/10]: The article includes perspectives from administration officials, industry, public health experts, and direct quotes from Makary, providing a broad range of viewpoints.

✕ Omission [8/10]: The article does not mention the FDA’s approval of flavored e-cigarettes by Glas, a significant recent decision potentially relevant to the White House’s dissatisfaction, despite it being known from other sources.

✕ Omission [10/10]: The article fails to mention the FDA’s recent approval of blueberry and mango flavored e-cigarettes by Glas, which is directly relevant given reports that Trump was frustrated with Makary over vape approvals.

✕ Cherry-Picking [7/10]: The article highlights criticism from pharmaceutical groups and antiabortion advocates but does not explain how or why antiabortion groups are engaged with Makary’s policies, potentially distorting the balance of opposition.

"faced scrutiny from pharmaceutical industry groups, antiabortion advocates and, at times, former FDA commissioners"

✓ Comprehensive Sourcing [9/10]: The article provides background on Makary’s appointment, Senate confirmation, and policy initiatives, giving readers context on his political and professional trajectory.

"The Senate confirmed Makary in March 2025 to lead the FDA, with three Democrats joining Republicans in the 56-44 vote, a rare instance of bipartisan support for a top Trump health pick."